Chemically modified tetracyclines as inhibitors of matrix metalloproteinases

Amin, 1997, Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines, FEBS Lett., 410, 259, 10.1016/S0014-5793(97)00605-4

Basset, 1993, Expression of the stomelysin gene in fibroblastic cells of invasive carcinoma of the breast and other human tissues: a review, Breast Cancer Res. Treat., 24, 185, 10.1007/BF01833259

Bergers, 1999, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice, Science, 284, 808, 10.1126/science.284.5415.808

Bettany, 2000, Tetracyclines induce apoptosis in osteoclasts, Bone, 27, 75, 10.1016/S8756-3282(00)00297-0

Bettany, 1998, Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells, Adv. Dent. Res., 12, 136, 10.1177/08959374980120010901

Blavier, 1999, Tissue inhibitors of matrix metalloproteinases in cancer, Ann. N.Y. Acad. Sci., 878, 108, 10.1111/j.1749-6632.1999.tb07677.x

Boolbol, 1996, Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis, Cancer Res., 56, 2556

Broxterman, 2003, Resistance to cytotoxic and anti-angiogenic agents: similarities and differences, Drug Resist. Update, 6, 111, 10.1016/S1368-7646(03)00026-8

Cancer Trials, 2001. National Cancer Institute (http://www.cancer.gov/clinical.htm).

Catterall, 2003, Assays of matrix metalloproteinases (MMPs) and MMP inhibitors: bioassays and immunoassays applicable to cell culture medium, serum, and synovial fluid, Methods Mol. Biol., 225, 353

Chambers, 1997, Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 89, 1260, 10.1093/jnci/89.17.1260

Chen, 2001, Biodistribution of radiolabeled [(3)H] CMT-3 in rats, Curr. Med. Chem., 8, 253, 10.2174/0929867013373615

Cianfrocca, 2002, Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: a phase I AIDS malignancy consortium study, J. Clin. Oncol., 20, 153, 10.1200/JCO.20.1.153

Cillari, 1998, Modulation of nitric oxide production by tetracyclines and chemically modified tetracyclines, Adv. Dent. Res., 12, 126, 10.1177/08959374980120010701

Coussens, 2002, MMP inhibitors and cancer: trials and tribulations, Science, 295, 2387, 10.1126/science.1067100

Curran, 1999, Matrix metalloproteinases in tumor invasion and metastasis, J. Pathol., 189, 300, 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C

D’Agostino, 2001, Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line, Int. Immunopharmacol., 1, 1765, 10.1016/S1567-5769(01)00100-X

D’Agostino, 2003, Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway, Int. Immunopharmacol., 3, 63, 10.1016/S1567-5769(02)00213-8

David, 1994, Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients, Cancer, 73, 518, 10.1002/1097-0142(19940201)73:3<518::AID-CNCR2820730305>3.0.CO;2-T

Duivenvoorden, 1997, Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells, Invasion Metast., 17, 312

Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer, 2, 161, 10.1038/nrc745

Eklund, 1999, Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells, Ann. N.Y. Acad. Sci., 878, 689, 10.1111/j.1749-6632.1999.tb07763.x

Fife, 1995, Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells, J. Lab. Clin. Med., 125, 407

Fife, 1998, Effects of doxycycline on human prostate cancer cells in vitro, Cancer Lett., 127, 37, 10.1016/S0304-3835(98)00003-2

Fife, 1997, Induction of apoptosis by doxycycline in cultured human osteosarcoma cells, J. Lab. Clin. Med., 130, 530, 10.1016/S0022-2143(97)90130-X

Fife, 2000, Effects of tetracyclines on angiogenesis in vitro, Cancer Lett., 153, 75, 10.1016/S0304-3835(00)00348-7

Fingleton, 1999, Matrilysin in early stage intestinal tumorigenesis, APMIS, 107, 102, 10.1111/j.1699-0463.1999.tb01532.x

Fong, 1996, TIMP-1 and adverse prognosis in non-small cell lung cancer, Clin. Cancer Res., 2, 1364

Gabler, 1992, Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions, Res. Commun. Chem. Pathol. Pharmacol., 78, 151

Gelmon, 1999, Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?, J. Natl. Cancer Inst., 91, 1281, 10.1093/jnci/91.15.1281

Gilbertson-Beadling, 1995, The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism, Cancer Chemother. Pharmacol., 36, 418, 10.1007/BF00686191

Golub, 1990, Reduction with tetracyclines of excessive collagen degradation in periodontal and other diseases, N.Y. State Dent. J., 56, 24

Golub, 1984, Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease, J. Periodont. Res., 19, 651, 10.1111/j.1600-0765.1984.tb01334.x

Golub, 1985, Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems, J. Periodontol., 56, 93, 10.1902/jop.1985.56.11s.93

Golub, 1985, Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources, J. Periodont. Res., 20, 12, 10.1111/j.1600-0765.1985.tb00405.x

Golub, 1987, A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity, J. Dent. Res., 66, 1310, 10.1177/00220345870660080401

Golub, 1991, Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs, Crit. Rev. Oral. Biol. Med., 2, 297, 10.1177/10454411910020030201

Golub, 1992, Tetracyclines (TCs) inhibit matrix metalloproteinases (MMPs): in vivo effects in arthritic and diabetic rats and new in vitro studies, Matrix, 1, 315

Golub, 1992, Host modulation with tetracyclines and their chemically modified analogues, Curr. Opin. Dent., 2, 80

Golub, 1998, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms, Adv. Dent. Res., 12, 12, 10.1177/08959374980120010501

Greenwald, R.A., Hillen, W., Nelson, M., 2001. Tetracyclines in Biology, Chemistry and Medicine. Basel, Boston, p. 336.

Gu, 2001, Inhibition of tumor cell invasiveness by chemically modified tetracyclines, Curr. Med. Chem., 8, 261, 10.2174/0929867013373642

Guay, 1993, Expression of the tetK gene from Staphylococcus aureus in Escherischia coli: comparison of substrate specifities of TetA(B), TetA(C), and TetK efflux proteins, Antimicrob. Agents Chemother., 37, 191, 10.1128/AAC.37.2.191

Gupta, 2002, 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents, Bioorg. Med. Chem., 10, 3713, 10.1016/S0968-0896(02)00421-2

Hanemaaijer, 1998, Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells, Adv. Dent. Res., 12, 114, 10.1177/08959374980120010301

Heath, 2000, Clinical potential of matrix metalloprotease inhibitors in cancer therapy, Drugs, 59, 1043, 10.2165/00003495-200059050-00002

Hendrix, 2003, Remodeling of the microenvironment by aggressive melanoma tumor cells, Ann. N.Y. Acad. Sci., 995, 151, 10.1111/j.1749-6632.2003.tb03218.x

Henriet, 1999, Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation, APMIS, 107, 111, 10.1111/j.1699-0463.1999.tb01533.x

Hess, 2003, Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry, Cancer Res., 63, 4757

Hewitt, 1991, Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours, Int. J. Cancer, 49, 666, 10.1002/ijc.2910490507

Hidalgo, 2001, Development of matrix metalloproteinase inhibitors in cancer therapy, J. Natl. Cancer Inst., 93, 178, 10.1093/jnci/93.3.178

Imren, 1996, Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion, Cancer Res., 56, 2891

Johansson, 2000, Matrix metalloproteinases in tumor invasion, Cell. Mol. Life Sci., 57, 5, 10.1007/s000180050495

Kahari, 1997, Matrix metalloproteinases in skin, Exp. Dermatol., 6, 199, 10.1111/j.1600-0625.1997.tb00164.x

Kahari, 1999, Matrix metalloproteinases and their inhibitors in tumor growth and invasion, Ann. Med., 31, 34, 10.3109/07853899909019260

Karameris, 1997, Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous lung carcinomas, Am. J. Respir. Crit. Care Med., 156, 1930, 10.1164/ajrccm.156.6.9612046

Karimbux, 1994, Tissue healing with doxycycline and chemically modified tetracycline treatments in rats with Porphyromonas gingivalis-induced periodontitis, Ann. N.Y. Acad. Sci., 732, 433, 10.1111/j.1749-6632.1994.tb24777.x

Kirkwood, 1999, Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts, Ann. N.Y. Acad. Sci., 878, 667, 10.1111/j.1749-6632.1999.tb07757.x

Kleiner, 1999, Matrix metalloproteinases and metastasis, Cancer Chemother. Pharmacol., 43, S42, 10.1007/s002800051097

Lauhio, 1994, The in vivo effect of doxycycline treatment on matrix metalloproteinases in reactive arthritis, Ann. N.Y. Acad. Sci., 732, 431, 10.1111/j.1749-6632.1994.tb24776.x

Lauhio, 1995, Tetracyclines in treatment of rheumatoid arthritis, Lancet, 346, 645, 10.1016/S0140-6736(95)91484-6

Lee, 2001, CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer, Curr. Med. Chem., 8, 257, 10.2174/0929867013373660

Li, 2002, Evidence for dissolution rate-limited absorption in COL-3, a MMPI, leading to the irregular absorption profile in rats after oral administration, Pharm. Res., 19, 1655, 10.1023/A:1020901328583

Liotta, 1990, Metalloproteinases and cancer invasion, Semin. Cancer Biol., 1, 99

Liotta, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen, Nature, 284, 67, 10.1038/284067a0

Liu, 2001, The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs), Curr. Med. Chem., 8, 243, 10.2174/0929867013373525

Llavaneras, 2001, A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats, J. Periodontol., 72, 1069, 10.1902/jop.2001.72.8.1069

Lokeshwar, 1999, MMP inhibition in prostate cancer, Ann. N.Y. Acad. Sci., 878, 271, 10.1111/j.1749-6632.1999.tb07690.x

Lokeshwar, 1998, Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer, Adv. Dent. Res., 12, 97, 10.1177/08959374980120012901

Lokeshwar, 2001, Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3), Curr. Med. Chem., 8, 271, 10.2174/0929867013373516

Lokeshwar, 2002, Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model, Int. J. Cancer, 98, 297, 10.1002/ijc.10168

Lopez-Otin, 2002, Protease degradomics, a new challenge for proteomics, Nat. Rev. Mol. Cell. Biol., 3, 509, 10.1038/nrm858

Lukkonen, 2000, Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration, Int. J. Cancer, 86, 577, 10.1002/(SICI)1097-0215(20000515)86:4<577::AID-IJC21>3.0.CO;2-J

Makela, 1998, The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration, Adv. Dent. Res., 12, 131, 10.1177/08959374980120010801

Mealey, 2002, Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells, Antimicrob. Agents Chemother., 46, 755, 10.1128/AAC.46.3.755-761.2002

Meng, 2000, Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells, Clin. Exp. Metastasis, 18, 139, 10.1023/A:1006732424102

Mitsiades, 2001, Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug, Exp. Opin. Investig. Drugs, 10, 1075, 10.1517/13543784.10.6.1075

Morin, 2003, Drug resistance and the microenvironment: nature and nurture, Drug Resist. Update, 6, 169, 10.1016/S1368-7646(03)00059-1

Munoz-Mateu, M., de’Grafenried, L., Eckhardt, S., Malik, S., Rizzo, J., Kuhn, J., Rowinsky, E., Hidalgo, M., 2001. Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 20 302 (abstract).

Myers, 1998, Tetracycline-based MMP inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro, Adv. Dent. Res., 12, 86, 10.1177/08959374980120012701

Nagase, 1999, Matrix metalloproteinases, J. Biol. Chem., 270, 21491, 10.1074/jbc.274.31.21491

Nelson, 2000, Matrix metalloproteinases: biologic activity and clinical implications, J. Clin. Oncol., 18, 1135, 10.1200/JCO.2000.18.5.1135

Overall, 2002, Strategies for MMP inhibition in cancer: innovations for the post-trial era, Nat. Rev. Cancer, 2, 657, 10.1038/nrc884

Patel, 1999, A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production, J. Immunol., 163, 3459, 10.4049/jimmunol.163.6.3459

Pinsuwan, 1999, Degradation kinetics of 4-dedimethylamino sancycline, a new anti-tumor agent, in aqueous solutions, Int. J. Pharm., 181, 31, 10.1016/S0378-5173(98)00417-7

Pinsuwan, 1999, Spectrophotometric determination of acidity constants of 4-dedimethylamino sancycline (Col-3), a new antitumor drug, J. Pharm. Sci., 88, 535, 10.1021/js980398l

Pirila, 2001, Wound healing in ovariectomized rats: effects of chemically modified tetracycline (CMT-8) and estrogen on matrix metalloproteinases-8, -13 and type I collagen expression, Curr. Med. Chem., 8, 281, 10.2174/0929867013373552

Pirila, 2002, Chemically modified tetracycline (CMT-8) and estrogen promote wound healing in ovariectomized rats: effects on matrix metalloproteinase-2, membrane type 1 matrix metalloproteinase, and laminin-5 gamma2-chain, Wound Repair Regen., 10, 38, 10.1046/j.1524-475X.2002.10605.x

Poulaki, 2001, The role of Fas and FasL as mediators of anticancer chemotherapy, Drug Resist. Update, 4, 233, 10.1054/drup.2001.0210

Powe, 1997, TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma, Br. J. Cancer, 75, 1678, 10.1038/bjc.1997.285

Pruzanski, 1998, Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2, J. Rheumatol., 25, 1807

Purcell, 2002, Development of matrix metalloproteinase inhibitors in cancer therapy, Hematol. Oncol. Clin. North Am., 16, 1189, 10.1016/S0889-8588(02)00044-8

Ratnikov, 2002, Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase, Lab. Invest., 82, 1583, 10.1097/01.LAB.0000038555.67772.DB

Rawal, 2001, Non-antimicrobial properties of tetracyclines—dental and medical implications, West Indian Med. J., 50, 105

Ray, 1994, The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis, Eur. Respir. J., 7, 2060, 10.1183/09031936.94.07112062

Rifkin, 1994, Modulation of bone resorption by tetracyclines, Ann. N.Y. Acad. Sci., 732, 165, 10.1111/j.1749-6632.1994.tb24733.x

Rowinsky, 2000, Protracted daily treatment of COL-3, an oral tetracycline analog, MMP inhibitor is feasible a phase I, pharmacokinetic, and biological study, Proc. Am. Soc. Clin. Oncol., 19, 700

Rowinsky, 2000, A phase I and pharmacokinetic PK study of COL-3 an oral tetracycline analog and selective MMP inhibitor, Clin. Cancer Res., 6, 292a

Rudek, 2000, High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma, J. Pharm. Biomed. Anal., 22, 1003, 10.1016/S0731-7085(00)00257-0

Rudek, 2001, Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J. Clin. Oncol., 19, 584, 10.1200/JCO.2001.19.2.584

Rudek, 2002, Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?, Pharmacotherapy, 22, 705, 10.1592/phco.22.9.705.34062

Ryan, 1998, Tetracyclines inhibit protein glycation in experimental diabetes, Adv. Dent. Res., 12, 152, 10.1177/08959374980120011201

Saikali, 2003, Doxycycline and other tetracyclines in the treatment of bone metastasis, Anticancer Drugs, 14, 773, 10.1097/00001813-200311000-00001

Schatzkin, 2002, The promise and peril of surrogate end-points in cancer research, Nat. Rev. Cancer, 2, 19, 10.1038/nrc702

Seftor, 1998, Application of chemically modified tetracyclines (CMTs) in experimental models of cancer and arthritis, Adv. Dent. Res., 12, 103, 10.1177/08959374980120010101

Seftor, 1998, Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis, Clin. Exp. Metastasis, 16, 217, 10.1023/A:1006588708131

Seftor, 2001, Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma, Cancer Res., 61, 6322

Seftor, 2002, Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry, Mol. Cancer Ther., 1, 1173

Selzer, 1999, CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer, Ann. N.Y. Acad. Sci., 878, 678, 10.1111/j.1749-6632.1999.tb07760.x

Smith, 1999, Specificity of inhibition of matrix metalloproteinase activity by doxycycline, Arthritis Rheum., 42, 1140, 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7

Sorsa, 1991, Collagenase inhibition by tetracyclines, Duodecim, 107, 1966

Stetler-Stevenson, 1996, MMP and tumor invasion: from correlation and casualty to the clinic, Semin. Cancer Biol., 7, 147, 10.1006/scbi.1996.0020

Talhouk, 1992, Coordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution, J. Cell. Biol., 118, 1271, 10.1083/jcb.118.5.1271

Taniguchi, 1992, Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cell line (SUIT-2) and sublines, Clin. Exp. Metast., 10, 259, 10.1007/BF00133561

Teicher, 1990, Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo, Science, 247, 1457, 10.1126/science.2108497

Tolomeo, 2001, Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines, Br. J. Pharmacol., 133, 306, 10.1038/sj.bjp.0704068

Trachtman, 1996, Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells, Biochem. Biophys. Res. Commun., 229, 243, 10.1006/bbrc.1996.1787

Tsuiji, 1997, Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential, Proc. Natl. Acad. Sci. U.S.A., 94, 3336, 10.1073/pnas.94.7.3336

Vernillo, A.T., Ramamurthy, N.S., Golub, L.M., Rifkin, B.R., 1994. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Curr. Opin. Periodontol., 111–118.

Weissleder, 2002, Scaling down imaging: molecular mapping of cancer in mice, Nat. Rev. Cancer, 2, 11, 10.1038/nrc701

West, 2002, Activation of the PI3K/Akt pathway and chemotherapeutic resistance, Drug Resist. Update, 5, 234, 10.1016/S1368-7646(02)00120-6

Wilson, 1997, Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin, Proc. Natl. Acad. Sci. U.S.A., 94, 1402, 10.1073/pnas.94.4.1402

Wysocki, 1993, Wound fluid from chronic leg ulcers contains elevated levels of MMP-2 and MMP-9, J. Invest. Dermatol., 101, 64, 10.1111/1523-1747.ep12359590

Yoshiji, 1996, Enhanced RNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human breast cancer, Br. J. Cancer, 69, 131

Yu, 1992, HPLC determination of a chemically modified nonantimicrobial tetracycline: biological implications, Biochem. Med. Metab. Biol., 47, 10, 10.1016/0885-4505(92)90003-H

Zeng, 1995, Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph nodes and distinct metastasis, Clin. Cancer Res., 1, 899